Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 15/20 | 0.66 |
| ▸ | ERCC4 | Q92889 | 15/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | GABRE | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175299 | 0.88 | ERCC1 (0.66) | ERCC1ERCC4TRPV1ALPGARG1 | |
| SCHEMBL28232328 | 0.87 | ERCC1 (0.59) | ERCC1ERCC4TRPV1GABRPGABRD | |
| SCHEMBL339753 | 0.86 | ERCC1 (0.59) | ERCC1ERCC4TRPV1GABRPGABRD | |
| SCHEMBL8269527 | 0.84 | KDM4E (0.69) | ERCC1ERCC4TRPV1ALPGALPL | |
| SCHEMBL107165 | 0.84 | ERCC1 (0.73) | ERCC1ERCC4TRPV1 | |
| SCHEMBL107237 | 0.82 | ERCC1 (0.81) | ERCC1ERCC4TRPV1 | |
| SCHEMBL108637 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4TRPV1 | |
| SCHEMBL141914 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4TRPV1 | |
| SCHEMBL107880 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4TRPV1 | |
| SCHEMBL13886076 | 0.82 | ERCC1 (0.51) | ERCC1ERCC4TRPV1ALPGALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8586585-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | PROTEOTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130245128-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2013-09-19 | — | — | US | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | ERCC1 2754/4885ERCC4 3932/4885TRPV1 363/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | ERCC1 4216/4885ERCC4 4094/4885TRPV1 4641/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | ERCC1 2635/4885ERCC4 2782/4885TRPV1 2857/4885 |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | ERCC1 3468/4885ERCC4 4102/4885TRPV1 4059/4885 |
| US-20130245128-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | ERCC1 2210/4885ERCC4 3639/4885TRPV1 3457/4885 |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | ERCC1 4117/4885ERCC4 4337/4885TRPV1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.